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Frontotemporal dementia is a heterogeneous neurodegenerative disorder with around a third of cases having autosomal dominant
inheritance. There is wide variability in phenotype even within affected families, raising questions about the determinants of the
progression of disease and age at onset. It has been recently demonstrated that cognitive reserve, as measured by years of formal
schooling, can counteract the ongoing pathological process. The TMEM106B genotype has also been found to be a modiﬁer of the
age at disease onset in frontotemporal dementia patients with TDP-43 pathology. This study therefore aimed to elucidate the
modulating effect of environment (i.e. cognitive reserve as measured by educational attainment) and genetic background (i.e.
TMEM106B polymorphism, rs1990622 T/C) on grey matter volume in a large cohort of presymptomatic subjects bearing
frontotemporal dementia-related pathogenic mutations. Two hundred and thirty-one participants from the GENFI study were
included: 108 presymptomatic MAPT, GRN, and C9orf72 mutation carriers and 123 non-carriers. For each subject, cortical and
subcortical grey matter volumes were generated using a parcellation of the volumetric T1-weighted magnetic resonance imaging
brain scan. TMEM106B genotyping was carried out, and years of education recorded. First, we obtained a composite measure of
grey matter volume by graph-Laplacian principal component analysis, and then ﬁtted a linear mixed-effect interaction model,
considering the role of (i) genetic status; (ii) educational attainment; and (iii) TMEM106B genotype on grey matter volume. The
presence of a mutation was associated with a lower grey matter volume (P = 0.002), even in presymptomatic subjects. Education
directly affected grey matter volume in all the samples (P = 0.02) with lower education attainment being associated with lower
volumes. TMEM106B genotype did not inﬂuence grey matter volume directly on its own but in mutation carriers it modulated the
slope of the correlation between education and grey matter volume (P = 0.007). Together, these results indicate that brain atrophy
in presymptomatic carriers of common frontotemporal dementia mutations is affected by both genetic and environmental factors
such that TMEM106B enhances the beneﬁt of cognitive reserve on brain structure. These ﬁndings should be considered in
evaluating outcomes in future disease-modifying trials, and support the search for protective mechanisms in people at risk of
dementia that might facilitate new therapeutic strategies.
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Introduction
Frontotemporal dementia (FTD) is a neurodegenerative dis-
order characterized by neuronal loss in the frontal and
temporal lobes (Hodges et al., 2004; Rohrer et al., 2011;
Warren et al., 2013). It presents clinically with behavioural
symptoms, deﬁcits of executive functions and language im-
pairment, and in some cases, with motor neuron disease,
progressive supranuclear palsy or corticobasal syndrome
(Seelaar et al., 2011). Up to 40% of cases have a family
history of dementia, with an autosomal dominant inherit-
ance in around a third of patients (Stevens et al., 1998).
Mutations within microtubule-associated protein tau
(MAPT) (Hutton et al., 1998), granulin (GRN) (Baker
et al., 2006; Cruts et al., 2006), and chromosome 9 open
reading frame 72 (C9orf72) (DeJesus-Hernandez et al.,
2011; Renton et al., 2011) are proven major causes of
genetic FTD, accounting for 10–20% of all FTD cases.
MAPT mutations lead to FTD with neuronal tau inclu-
sions, while GRN and C9orf72 are associated with intra-
neuronal TAR DNA-binding protein 43 (TDP-43)
inclusions (Baborie et al., 2011).
Recently, it has been demonstrated in the Genetic
Frontotemporal Dementia Initiative (GENFI) study that
grey matter and cognitive changes can be identiﬁed 5–10
years before the expected onset of symptoms in adults at
risk of genetic FTD (Rohrer et al., 2015), and even earlier
for those with C9orf72 expansions. However, there is wide
variation in the age at onset within families, and possible
modiﬁers of disease progression (including genetic and en-
vironmental factors) have yet to be investigated. Such
modiﬁers will be important for several reasons: to properly
deﬁne biomarkers that can stage presymptomatic disease
and track disease progression, to correctly identify individ-
uals most suitable for clinical trials, and to reduce hetero-
geneity and increase the statistical power of analyses of
such trials.
Cognitive reserve and genetic factors have both been pro-
posed as moderators of the onset of disease. Cognitive re-
serve is a theoretical concept proposing that certain lifetime
experiences, including education, individual intelligence
quotient, degree of literacy, and occupational attainment,
increase the ﬂexibility, efﬁciency, and capacity of brain net-
works, thereby allowing individuals with higher cognitive
reserve to sustain greater levels of brain pathology before
showing clinical impairment (for a review, see Stern, 2009).
In healthy individuals, higher educational attainment
(Arenaza-Urquijo et al., 2013) as well as cognitive enrich-
ment (Sun et al., 2016) have been related to greater volume
and greater metabolism in frontotemporal regions, thus
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likely enhancing brain performance (Barulli and Stern,
2013).
Genetic modiﬁers of disease expression also exist, affect-
ing the phenotype and prognosis. TMEM106B has been
identiﬁed as a genetic modiﬁer in FTD, modulating the
age at disease onset in frontotemporal lobar degener-
ation–TDP-43 disease (Cruchaga et al., 2011; Gallagher
et al., 2014; van Blitterswijk et al., 2014). The
TMEM106B rs1990622 TT genotype is detrimental and
associated with earlier age at disease onset (Cruchaga
et al., 2011) and greater functional impairment in frontal
regions in presymptomatic GRN mutation carriers (Premi
et al., 2014). Conversely, the role of this polymorphism in
C9orf72 mutation carriers is still unclear, as it has been
suggested a detrimental effect of TMEM106B rs1990622
CC genotype on disease onset and death (Deming and
Cruchaga, 2014; Gallagher et al., 2014; van Blitterswijk
et al., 2014).
In this study, we aimed to evaluate modiﬁers of structural
brain changes in presymptomatic mutation carriers from a
large international cohort of subjects at risk for genetic
FTD, investigating the effect of (i) pathogenetic mutation,
i.e. MAPT, GRN and C9orf72 carriers versus non-carriers;
(ii) cognitive reserve, as measured by years of formal
schooling; and (iii) TMEM106B rs1990622 genotype, and
their interaction, on grey matter volume.
We hypothesized that individually and together, these
three factors will modulate the degree of structural atrophy.
Materials and methods
Participants
Data for this study were drawn from the GENFI multicentre
cohort study (Rohrer et al., 2015), which consists of 13 re-
search centres in the UK, Italy, The Netherlands, Sweden, and
Canada. Inclusion and exclusion criteria have been previously
described (Rohrer et al., 2015). Local ethics committees
approved the study at each site and all participants provided
written informed consent according to the Declaration of
Helsinki. For the aim of the present work, we considered par-
ticipants at 50% risk of carrying a GRN, C9orf72 or MAPT
mutation based on having a ﬁrst-degree relative who was a
known symptomatic mutation carrier. Between January 2012
and April 2015, 365 participants were recruited into GENFI,
of which 294 were at risk and 71 symptomatic. Of the 294 at-
risk participants, 22 did not have a T1-weighted MRI scan
suitable for volumetric analysis. Included at-risk subjects
underwent a careful recording of demographic data, including
years of formal schooling (education), past medical history,
and a standardized clinical and neuropsychological assessment,
as previously published (Rohrer et al., 2015). Genotyping was
then performed for the TMEM106B rs1990622 (C/T) single
nucleotide polymorphism according to standard procedures
(Premi et al., 2014) (at the individual sites in 70.6% of
cases, and at the University of Brescia, Italy in the remaining
29.4%). Genotype was not available for 41 participants, and
so the ﬁnal analysis was performed on 231 participants: 108
presymptomatic mutation carriers [genetic status (GS) = 1], 61
with GRN, 33 with C9orf72 and 14 with MAPT mutations)
and 123 non-carriers (GS = 0)]. Participants (GS = 0 and
GS = 1) came from 77 families (15 with MAPT, 33 with
GRN, and 29 with C9orf72 mutations). TMEM106B geno-
type distribution was comparable between groups (GS = 0
versus GS = 1, Pearson 2 test, P = 0.958), as well as among
GS = 1 subgroups (i.e. GRN, C9orf72 and MAPT mutation
carriers, P = 0.419). Demographic characteristics of GS = 1,
subgrouped on the basis of mutation type, and GS = 0 are
reported in Table 1. Mean age of GS = 1 was 45.9 years
(range 20.5–70.5 years) and of GS = 0 was 48.3 years (range
19.4–85.7 years). No signiﬁcant differences were found in age,
gender, years of education, and neuropsychological tests be-
tween the groups.
Imaging analysis
T1-weighted volumetric MRI scans were parcellated into cor-
tical and subcortical regions as previously described (Rohrer
et al., 2015), using an atlas propagation and label fusion strat-
egy (Cardoso et al., 2015), combining regions of interest to
calculate grey matter cortical volumes (separated into the fron-
tal, temporal, parietal, occipital, cingulate, and insular cortices),
subcortical volumes (hippocampus, amygdala, caudate, puta-
men, accumbens, pallidum, and thalamus), cerebellum volume
(http://www.neuromorphometrics.org:808/seg/) (Diedrichsen
et al., 2009). Whole-brain volumes were measured using a
semi-automated segmentation method (Freeborough et al.,
1997). All measures were expressed as a percentage of total
intracranial volume (measured with SPM12 with a combination
of grey matter, white matter, and CSF segmentations).
Statistical analysis
We ﬁtted a linear mixed effect interaction model (Galecki and
Burzykowski, 2013). We assessed the main effect of three fac-
tors on grey matter: (i) the presence of pathogenetic mutation
(GS, coded as GS = 1 for GRN, MAPT or C9orf72 mutation
carriers and GS = 0 for mutation non-carriers); (ii) the role of
cognitive reserve as measured by years of formal education;
and (iii) the TMEM106B rs1990622 C/T genotype (coded as
CC, CT or TT). The relationship between each factor and grey
matter volume was labelled as b1, b2, and b3, respectively
(Fig. 1, dark blue lines). Furthermore, we considered the
two-way interaction effect of each factor (i.e. GS and educa-
tion, labelled as b4 (red line), GS and TMEM106B genotype,
labelled as b5 (orange line), and education and TMEM106B
genotype, labelled as b6 (green line) (Fig. 1). Finally, we con-
sidered the three-way interaction effect, i.e. GS, education, and
TMEM106B genotype, on grey matter (b7) (Fig. 1). These
main and interaction effects were adjusted by ﬁxed covariates,
namely age and gender. Moreover, we considered two random
effect factors, study site and pedigree, which permitted analysis
of the correlations of subjects in the same cluster (centres of
subjects’ enrolment or individual families).
To overcome the complexity of multiple comparison correc-
tions, we ﬁrst carried out data reduction of grey matter par-
cellation data. We proposed a graph-Laplacian Principal
Component Analysis (gLPCA) to obtain a low dimensional
representation of grey matter parcellation, which incorporated
graph structure (Jiang et al., 2013). We did not apply principal
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component analysis (PCA), widely used to obtain a low-dimen-
sional representation, as the imaging data presented spatial
distribution and high left-right correlation (Belkin and
Niyogi, 2001). Graph-Laplacian PCA (gLPCA) has several ad-
vantages: (i) it is modelled on the representation of the data;
(ii) it can be easily calculated, presenting a compact closed-
form solution; and (iii) it allows noise removal. Once we ob-
tained data reduction, bivariate correlations between principal
component (PC) scores and each grey matter measure were
computed. Finally, we ﬁtted the mixed-effect interaction
models with grey matter, summarized by the ﬁrst PC scores,
as outcome variable. Statistical analysis was performed via R
packages (www.r-project.org) and in-house R scripts.
Results
By gLPCA using the skeleton graph between grey matter
measures (Supplementary Fig. 1), the ﬁrst PC (PC1) was
selected to summarize the grey matter volume data.
Frontal, parietal and temporal regions were the areas that
contributed most to graph construction and PC1 scores,
based on correlations between PC1 scores and grey
matter measures (Supplementary Table 1).
Fitting the linear mixed-interaction model with ﬁxed cov-
ariates (age and gender) and random effects (study site and
pedigree), a signiﬁcant direct effect of GS and years of
Table 1 Demographic and clinical characteristics and TMEM106B genotype in the studied groups
GS = 0
(n = 123)
GS = 1
(n = 108)
C9orf72
(n = 33)
GRN
(n = 61)
MAPT
(n = 14)
P-value
Age, years 48.3  14.4 45.9  11.3 43.6  10.5 49.4  10.6 36.4  9.5 0.164*
Gender, % female (n) 63.4 (78) 64.8 (70) 57.6 (19) 65.6 (40) 78.6 (11) 0.891†
Education, years 13.7  3.3 14.0  3.1 13.8  3.1 14.0  3.2 14.3  2.6 0.596*
TMEM rs1990622 0.958†
C/C (%) 11.4 (14) 10.1 (11) 9.1 (3) 9.8 (6) 14.3 (2)
C/T (%) 51.2 (63) 51.9 (56) 51.5 (17) 57.4 (35) 28.6 (4)
T/T (%) 37.4% (46) 38.0 (41) 39.4 (13) 32.8 (20) 57.1 (8)
Neuropsychological evaluation
CBI-Revised 3.28  5.13 3.78  7.00 5.14  6.54 3.26  7.70 3.07  4.71 0.402#
MMSE 29.22  1.25 29.14  1.33 29.12  1.32 29.00  1.41 29.77  0.83 0.211#
Logical Memory-Immediate Recall 0.54  1.48 0.68  1.45 0.76  1.57 0.50  1.35 1.25  1.51 0.608#
Logical Memory-Delayed Recall 0.22  1.10 0.33  1.13 0.44  1.23 0.19  1.09 0.66  1.03 0.597#
Digit Span forwards 0.11  1.02 0.02  1.03 0.12  1.12 0.03  1.02 0.28  0.84 0.225#
Digit Span backwards 0.03  0.95 0.15  0.92 0.06  1.01 0.24  0.86 0.05  0.99 0.311#
Trail Making Test Part A 0.29  0.75 0.28  0.63 0.22  0.62 0.22  0.63 0.71  0.52 0.352#
Trail Making Test Part B 0.29  0.76 0.30  0.83 0.21  1.09 0.28  0.66 0.62  0.72 0.565#
Digit Symbol Task 0.34  1.05 0.38  1.00 0.34  0.96 0.22  0.96 1.14  0.98 0.575#
Boston Naming Test 0.10  0.88 0.11  0.97 0.13  1.15 0.29  0.68 0.08  1.41 0.933#
Letter Fluency 0.22  1.02 0.21  0.98 0.38  0.94 0.09  0.92 0.38  1.27 0.593#
Category Fluency 0.02  1.07 0.15  1.32 0.89  1.12 0.23  1.32 0.02  1.01 0.281#
Block Design 0.04  0.99 0.15  1.07 0.24  1.24 0.21  0.94 0.78  0.83 0.799#
GS = 0: mutation non-carriers; GS = 1: mutation carriers.
CBI = Cambridge Behavioural Inventory; MMSE = Mini-Mental State Examination.
Results are expressed as mean  standard deviation or otherwise indicated. P-values, GS = 1 versus GS = 0 comparison: *Student t-test; †2 Chi-Square test; #one-way ANCOVA
(expressed as Z-scores).
Figure 1 Model design and results of interaction model on
grey matter volume. b1, b2, b3: main effect relationship of each
factors (dark blue lines); b1: pathogenetic mutation (GRN, MAPT or
C9orf72); b2: cognitive reserve as measured by years of formal
education, and b3: TMEM106B rs1990622 polymorphism (coded as
TT, TC and CC). b4, b5, b6: two-way interaction effect of each
factor [b4: genetic status and education (red line), b5: genetic status
and TMEM106B (orange line), and b6 (green line): education and
TMEM106B]. b7: three-way interaction effect (genetic status, edu-
cation, and TMEM106B) on grey matter volume (purple line).
ROI = region of interest.
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education on grey matter outcome (PC1 scores) was
observed (P = 0.002 and P = 0.02, respectively), while no
effect of TMEM106B genotype on grey matter was de-
tected. We did not ﬁnd any signiﬁcant two-way interaction
between the considered variables, but did ﬁnd a three-way
interaction on grey matter (P = 0.007) (Table 2).
The data are summarized in Fig. 2. On the x-axis, years
of education (i.e. cognitive reserve) are reported, and on the
y-axis grey matter volume (PC1). Years of education had a
signiﬁcant direct effect on grey matter volume, independ-
ently of GS. We found that the greater the years of educa-
tion, the greater the grey matter volume (in both GS = 0
and GS = 1), suggesting that cognitive reserve was able to
exert an effect in presymptomatic at-risk participants carry-
ing pathogenetic mutations as well as in non-carriers, by
increasing grey matter volume.
In comparison to non-carriers (GS = 0, red line), muta-
tion carriers (GS = 1, blue line) showed a signiﬁcant de-
crease of grey matter volume, conﬁrming the effect of
pathogenetic mutations in shaping progressive atrophy
before the onset of symptoms (Rohrer et al., 2015).
The TMEM106B genotype did not exert a direct effect
on grey matter volume, and it did not affect grey matter
(Fig. 2, red line, GS = 0 and TMEM106B CC or CT or
TT). However, in those individuals carrying pathogenetic
mutations (GS = 1), TMEM106B polymorphism modulated
the slope of the relationship between education and grey
matter volume (GS*Education*TMEM106B): a steeper
slope was found in TMEM106B TT carriers compared
with CT carriers, which in turn was greater than that of
CC carriers, with a dose-dependent effect (Fig. 2, green and
purple lines). Considering the contribution of each muta-
tion separately, the effect of TMEM106B genotype
(GS*Education*TMEM106B) was mainly driven by
C9orf72 mutation carriers, the subgroup of patients with
the greatest atrophy (Supplementary Table 2 and
Supplementary Fig. 2).
Discussion
Autosomal dominant FTD presents with signiﬁcant inter-
and intra-familial variability among individuals bearing the
same pathogenetic mutation. This suggests the presence of
environmental, genetic and/or epigenetic modiﬁers, inﬂuen-
cing the age at disease onset and clinical phenotype
(Borroni and Padovani, 2013). The effect of genetic modi-
ﬁers and environmental factors that might trigger the onset
of neurodegeneration in carriers of the pathogenetic muta-
tion (which is present at birth but only manifests symptoms
in mid-late adulthood) are of extreme interest. In this view,
the pathogenesis of inherited FTD may be a model of
Table 2 Output from the linear mixed effect interaction model
Fixed effects b Estimate SE Z-value P-value
GS b 1 0.262 0.084 3.120 0.002
Education b 2 0.035 0.015 2.350 0.020
TMEM106B b 3 0.035 0.066 0.522 0.600
GS*Education b 4 0.046 0.027 1.729 0.080
GS  TMEM106b b 5 0.055 0.133 0.413 0.680
Education  TMEM106b b 6 0.0005 0.020 0.025 0.980
GS  Education  TMEM106b b 7 0.110 0.041 2.700 0.007
Age  0.052 0.003 14.58 50.001
Gender  0.527 0.088 6.008 50.001
Random effects Variance SE
Pedigree (no. groups = 77)  0.085 0.290
Site (no. groups = 13)  0.004 0.063
TMEM106B = TMEM106B rs1990622 polymorphism; SE = standard error; random effects = variance of the random intercept between groups.
Bold values represent significant values of the studied effect (b1, b2, b7), as reported by P values column.
Figure 2 Summary of the results from the fitted inter-
action model. x-axis, education attainment (years) y-axis, grey
matter volume as obtained by considering principal component (PC)
1, GS = 1: mutation carriers; GS = 0: mutation non-carriers;
TMEM = TMEM106B. See ‘Results’ section for details.
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‘Latent Early-Life Associated Regulation’ (LEARn), in
which latent expression of associated genes is triggered by
environmental and non-environmental factors (Maloney
et al., 2012; Maloney and Lahiri, 2016), with neurodegen-
eration being modulated by lifetime exposure to one or
more environmental factors as well as genetic background.
In the present study, we aimed at identifying modulating
factors of neuronal loss in presymptomatic subjects bearing
pathogenetic mutations within GRN, MAPT and C9orf72
genes through the surrogate marker of volumetric MRI.
We analysed the effect of (i) pathogenetic mutations;
(ii) cognitive reserve as measured by years of schooling;
and (iii) TMEM106B genotype on grey matter volume in
the large GENFI cohort. Indeed, we chose grey matter
volume as an endpoint measure as it correlates well with
indexes of disease severity (Premi et al., 2016) and progres-
sion (Brambati et al., 2007; Lam et al., 2014).
First, we conﬁrmed, as previously reported (Rohrer et al.,
2015), that pathogenetic mutations are detrimental to grey
matter volume years before expected age at disease onset,
being associated with smaller volumes i.e. greater atrophy
as compared to siblings who did not inherit the mutation.
C9orf72 repeat expansion carriers had a greater degree of
atrophy (Rohrer et al., 2015), as compared to GRN muta-
tion carriers and MAPT mutation carriers, with the latter
being the smallest group in our sample.
Furthermore, we demonstrated that cognitive reserve is
associated with brain atrophy and also modulate neuronal
loss years before the onset of symptoms. TMEM106B poly-
morphism, on the other hand, only modulated grey matter
volume in those with an autosomal dominant mutation and
with the lowest education.
The duration of formal schooling, as a proxy of cognitive
reserve, was associated with greater grey matter volume in
both non-carriers and in mutation carriers. This might sug-
gest that those subjects with higher educational attainment
were able to better counteract the detrimental effect of a
pathogenetic mutation than their counterparts with lower
education. However, this effect was also found in the group
that did not carry mutations: those with higher education
attainment had greater grey matter volume then those with
low education. Hence the ﬁnding is not speciﬁc to mutation
carriers suggesting a broader effect of cognitive reserve
on maintaining and ameliorating brain functioning.
Interestingly, even if presymptomatic mutation carriers al-
ready had mild structural changes (Rohrer et al., 2015), the
relationship between years of education and structural
changes was comparable to that observed in non-carriers
(direct correlation, the higher the education the greater the
grey matter volume) (Sole-Padulles et al., 2009; Rzezak
et al., 2015), rather than that reported in symptomatic
FTD (inverse correlation, the higher the education the
lower grey matter volume) (Borroni et al., 2009). The con-
cept of cognitive reserve was originally proposed to explain
the lack of a direct relationship between the degree of brain
pathology and the severity of the clinical manifestations
that should supposedly result from such damage in
neurodegenerative disorders such as Alzheimer’s disease
(Stern et al., 1992, 1994) and FTD (Borroni et al., 2009;
Premi et al., 2012, 2013). Cognitive reserve represents the
hypothesized capacity of the adult brain to compensate for
the effects of a disease or injury that would be sufﬁcient to
cause clinical dementia in an individual with less cognitive
reserve (Stern, 2002). Herein, we propose that high educa-
tion might postpone the onset of dementia in those subjects
at risk of developing FTD (Akbaraly et al., 2009; Craik
et al., 2010; Pettigrew et al., 2013). These ﬁndings extend
previous results obtained in healthy subjects (Sole-Padulles
et al., 2009; Rzezak et al., 2015), and might represent a
possible strategy to delay onset of inherited FTD.
Conversely to education attainment, TMEM106B geno-
type did not have any effect on mutation free individuals,
but this genetic trait might represent an additional non-
modiﬁable risk factor in mutation carriers. Literature data
have widely proven that TMEM106B variants are genetic-
ally associated to frontotemporal lobar degeneration–TDP-
43 pathology and are considered a major risk factor for
this disease (Chen-Plotkin et al., 2012; Busch et al., 2013;
Nicholson and Rademakers, 2016). It has been suggested
that the TMEM106B polymorphism might modulate pro-
granulin plasma levels, thus affecting age at onset of symp-
toms in GRN mutation carriers and explaining in part the
reported variability (Cruchaga et al., 2011). Furthermore,
presymptomatic GRN mutation carriers bearing the
TMEM106B TT genotype showed greater functional
brain damage than those with CT/CC TMEM106B geno-
types (Premi et al., 2014). In frontotemporal lobar degen-
eration–TDP-43 due to C9orf72 mutations, the relationship
is less clear, and it has been suggested that TMEM106B
might be able to affect disease pathology, but with an op-
posite association (Gallagher et al., 2014; van Blitterswijk
et al., 2014): two independent groups analysed the associ-
ation of TMEM106B variants with disease risk, age at
onset, and age at death in C9orf72 expansion carriers
with the CC genotype (protective in GRN carriers) found
to be associated with earlier onset and earlier death in
C9orf72 expansion carriers (Deming and Cruchaga, 2014;
Gallagher et al., 2014; van Blitterswijk et al., 2014). This
effect may be an example of the general phenomenon of
epistasis, in which a genetic variant is beneﬁcial on some
genetic backgrounds but deleterious in others (Gallagher
et al., 2014; Busch et al., 2016). In particular, as hypothe-
sized, if in GRN-related TDP-43 pathology TMEM106B is
related to endosomal-lysosomal dysfunction and to the per-
turbation of the progranulin pathway, in C9orf72 knock-
down mice TMEM106B over-expression may produce a
phenotypic rescue effect (Busch et al., 2016). However, fur-
ther studies are needed to elucidate its mechanism of
action. Another possibility is that TMEM106B is simply
in linkage disequilibrium with the actual associated variant
and when different populations are examined, the allele
associated with disease modulation is different.
In the present work, a moderating, dose dependent effect of
TMEM106B rs1990622 genotype together with education
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attainment was observed on grey matter volume in presymp-
tomatic subjects carrying pathogenetic mutations. This ﬁnd-
ing supports the idea that epigenetic modiﬁcations in
TMEM106B might occur. Epigenetic mechanisms, mostly
mediated by DNA methylation, have been shown to be im-
portant in other neurodegenerative disorders (Piaceri et al.,
2015) and to be inﬂuenced by socioeconomic status, which is
strongly associated with cognitive reserve (Tehranifar et al.,
2013). Thus, it could be hypothesized that TMEM106B, a
gene containing a number of methylation sites (http://genome.
ucsc.edu), might exert its effect on structural changes in at-
risk subjects via cognitive reserve. Future studies, however,
need to be performed to conﬁrm this hypothesis.
We indeed found a detrimental effect of the CC genotype,
but the present results were mainly driven by subjects car-
rying C9orf72 mutations, in which CC is the risk genotype
(Supplementary Table 2).
We acknowledge that there are limitations with this
work. First, the correlation between the factors herein con-
sidered and age at disease onset would beneﬁt from longi-
tudinal follow-up and independent studies to conﬁrm the
present results. The lack of assessment of leisure activities
prevents us from characterizing the entire spectrum of cog-
nitive reserve proxies (Nucci et al., 2012), and we are
aware of possible biases determined by different school sys-
tems across the involved countries. Finally, the role of
TMEM106b genotype should be further evaluated in the
different genetic groups alone.
In conclusion, our ﬁndings indicate that even several years
before the onset of symptoms, brain changes in inherited FTD
may be modulated by environmental and genetic factors. In
the absence of effective pharmacotherapeutic treatments for
counteracting the onset of symptoms in pathogenetic muta-
tion carriers, high education may represent a large-scale strat-
egy to be considered by national health system policies.
TMEM106b genotype needs to be considered as an extra
non-modiﬁable trait affecting brain pathology, and each
FTD mutation should be analysed individually. Future clin-
ical trials in genetic FTD should take into account both
education level and TMEM106b genotype to deﬁne sub-
jects with greater brain damage, thus representing those
at higher risk of developing FTD at an earlier age.
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